Lipid-Lowering Agents: Efficacy, Combinations, and Clinical Evidence

Ezetimibe

LDL ↓: Yes; TG ↓: No/none listed; Combo with statin: Yes; Clinical trial evidence for CV event reduction: Yes (marked *)

Bile acid sequestrants

LDL ↓: Yes; TG ↓: May raise TG; Combo with statin: Yes; Clinical trial evidence for CV event reduction: Yes (marked *)

Fibrate

LDL ↓: (not listed as primary); TG ↓: Yes; Combo with statin: Yes (fenofibrate preferred); Clinical trial evidence for CV event reduction: Yes (marked *)

Niacin

LDL ↓: Yes; TG ↓: Yes; Combo with statin: Yes; Clinical trial evidence for CV event reduction: No asterisk on slide

Omega-3 Fatty Acids

LDL ↓: May raise LDL; TG ↓: Yes; Combo with statin: Yes; Clinical trial evidence for CV event reduction: Yes (marked *)

PCSK9 Inhibitors

LDL ↓: Yes; TG ↓: (not listed as primary); Combo with statin: Yes; Clinical trial evidence for CV event reduction: Yes (marked *)

Bempedoic Acid

LDL ↓: Yes; TG ↓: (not listed); Combo with statin: Yes; Clinical trial evidence for CV event reduction: Yes (marked *)

Inclisiran

LDL ↓: Yes; TG ↓: (not listed); Combo with statin: Yes; Clinical trial evidence for CV event reduction: No asterisk on slide

Mipomersen

LDL ↓: Yes; TG ↓: (not listed); Combo with statin: Yes; Clinical trial evidence for CV event reduction: No asterisk on slide

Lomitapide

LDL ↓: Yes; TG ↓: (not listed); Combo with statin: Yes; Clinical trial evidence for CV event reduction: No asterisk on slide